CLINAPTIS RESEARCH
Browse Learn
GUIDE · TRIAL DISCLOSURES

Clinical Trial Disclosure Tracking

Turn a stream of trial updates into a documented record of what changed, what remains uncertain and which assumptions deserve review.

By Bikram K. Singh, MBBS · Last updated 18 October 2026. BioCo examples are fictional teaching illustrations; their dates and figures are assumptions.

Track the Question Behind the Catalyst

A trial update matters when it changes what you can reasonably assume about an asset. Begin with a specific question: is recruitment progressing, has the study changed, or is the evidence needed for the next decision now available? A list of announcements becomes useful research when each entry connects a source to an assumption and a follow-up action.

Keep three layers separate: reported fact—what the document says; interpretation—what you think it means; and decision—what you will investigate or change. A later readout date is a fact about guidance. Its cause and its implications require further evidence.

Use Each Source for the Right Question

An analyst’s source map
SourceUse it to establishCheck before concluding
Trial registry and historyThe registered design, status and successive public record versions.Whether a field is estimated or actual; when the update became public.
Protocol and amendmentsThe planned study procedures and documented changes.Version, effective date and the reason given for an amendment.
Statistical analysis planThe planned analyses, populations and decision rules.Which version applied and whether it preceded the relevant analysis.
Company release or filingWhat the sponsor announced about data, timing or strategy.What supporting tables, methods or explanations remain unavailable.
Abstract, presentation or publicationThe results and methods reported at that stage.Data cutoff, follow-up, denominators and differences from earlier reports.

Start with the registry’s guide to reading a study record, then retain the underlying documents for the particular question. The table is a practical research framework; no single source should be expected to answer every question.

ClinicalTrials.gov: reading a study record

Separate Study Dates From Disclosure Dates

ClinicalTrials.gov distinguishes submission dates from posting dates; they can differ. When reconstructing what was publicly knowable, retain the posting date alongside the date a sponsor submitted an update. Also record your own review date.

ClinicalTrials.gov: how to read a study record (Study Record Dates)

The primary completion date concerns collection of primary-outcome data. It is different from a company’s expected results announcement. Keep estimated and actual dates distinct, and do not turn either a registry completion estimate or an old presentation into a promised readout date.

ClinicalTrials.gov: protocol data definitions
DEFINITION · TWO COMPLETION DATESPrimary completion date: the date the final participant was examined or received an intervention for final collection of data for the primary outcome.Study completion date: the same, for the primary and secondary outcomes and adverse events.Either can be an estimate until the sponsor updates it to the actual date. Neither is a results-announcement date. Source: ClinicalTrials.gov protocol data definitions.

Use Record History to compare versions, retaining the earlier and later records. A public registry change is evidence that the record was updated; it does not by itself establish when an operational change occurred or why.

ClinicalTrials.gov: example Record History

Build a Disclosure Log You Can Revisit

Suggested fields for a manual disclosure log
Field groupRecord
IdentityCompany; asset; indication; NCT identifier; study name.
Source trailDocument title and link; version; document date; public posting date where available; date reviewed.
Observed changeEarlier wording or value; later wording or value; relevant section or page.
Study contextPhase; comparator; population; endpoints; enrollment; status; timing; data cutoff when results are reported.
InterpretationAffected assumption; plausible explanations; supporting and conflicting evidence.
Follow-upOpen question; next document or disclosure to check; review status.

Use one entry per material change. Preserve the original wording when it matters, rather than replacing it with a summary that obscures the comparison. A spreadsheet is enough to establish the workflow; automation can follow once the fields prove useful.

Compare Before You Explain

  • Confirm that both disclosures concern the same trial, cohort, indication and analysis.
  • Compare the previous and current design, population, endpoints, enrollment and dates.
  • Check whether a difference is an amendment, a correction, a refreshed estimate or a newly available result. Record “not established” when the explanation is absent.
  • If result summaries differ, reconcile data cutoffs, follow-up periods and analysis populations before treating the difference as a contradiction.
  • Write a follow-up question before assigning a valuation consequence.

Adaptive designs allow changes specified in advance and triggered by accumulating trial data. That does not mean every amendment is an adaptation or that a trial can be redesigned freely after seeing results. Check the planned rules and the documented change.

FDA: adaptive designs for drugs and biologics, Section II

Treat Designations as Context

Fast Track and Breakthrough Therapy concern development and review; Priority Review concerns the application review timetable; Accelerated Approval is a distinct approval pathway. Record which program applies and the sponsor’s stated implications. None is a substitute for reading the clinical evidence.

FDA: expedited development and review pathways

Orphan designation can bring incentives, including potential seven-year exclusivity following approval. Designation itself does not establish an approved product or a universal commercial premium.

FDA: orphan designation

Do not build a fixed time or cost adjustment into a model because a designation was granted. Take any adjustment from the program’s own timetable and the sponsor’s disclosed plans.

BioCo: A Timing Update

Fictional scenario. BioCo previously guided to a first-half readout. A later release moves guidance to the second half. Separately, the registry’s estimated primary completion date moves from March to June. No explanation is provided.

Keep observation, inference and action separate
LayerEntry
ObservedReadout guidance and estimated primary completion both move later. Save each dated source.
Not establishedWhether enrollment, follow-up, data cleaning or another factor explains the change.
InterpretationThe development timetable needs review; the trial’s eventual outcome remains unknown.
ActionCheck recruitment updates and the next filing. Test the stated timing change against the existing cash and development assumptions.

Do not count the same delay twice by adding the registry shift to the guidance shift. They may describe overlapping parts of one revised timetable. First reconcile the dates.

Translate Evidence Into a Model Review

Use the sequence disclosure → affected assumption → evidence gap → action. A timing change may call for a timing scenario. A result may call for a reassessment of the target population or development path. Make the proposed change explicit and retain the earlier assumption.

SEQUENCE · FROM DISCLOSURE TO MODEL REVIEWDisclosure → Affected assumption → Evidence gap → ActionBioCo example: guidance moves to the second half → the development timetable → the cause is not established → check recruitment updates and test a timing scenario.

Historical phase-transition rates can inform a starting assumption only when their population, period and definition match the question. They are not the probability that this particular trial will succeed. Nor does completing a phase automatically justify a fixed valuation increase.

If a program stops, review rights, alternative indications, contractual obligations, wind-down costs and remaining spending before changing its value. An abandoned development path does not mechanically set every related asset or obligation to zero.

Continue: Interpreting Clinical Trial Results →

Sources & Further Reading

Primary references for the methods discussed above. The disclosure log and BioCo examples are Clinaptis teaching frameworks, rather than records of an actual trial.

Educational content, not investment advice. Terms